For example, activating EGFR and ERBB2 mutations are considered positive predictive markers for therapy with tyrosine kinase inhibitors against receptors of the EGFR-family in non-small cell lung cancer (EGFR) and colorectal cancer (ERBB2)23,24. Here, EGFR is linked to non-small cell lung carcinoma.